Speaker illustration

Professor Anna Norhammar

Karolinska Institute, Stockholm (Sweden)

Member of:

European Society of Cardiology

SGLT2 inhibitors and atherosclerosis-related outcomes: the good and the bad

Event: ESC Congress 2019

Topic: Diabetes and the Heart

Session: SGLT2 inhibitors and cardiovascular outcomes


State of the Art in antidiabetic treatment to prevent CVD

Event: ESC Congress 2019

Topic: Pharmacotherapy

Session: The right glucose-lowering drugs for the right patient


Heart failure and death in new users of SGLT2 inhibitors vs other glucose-lowering drugs - consistent risk reduction across patient groups in 4 countries and >270,000 patients: The CVD-REAL Study

Event: ESC Congress 2017

Topic: Heart failure, other

Session: Late-Breaking Science in Heart Failure


Dapagliflozin is associated with lower risk of hospitalization for heart failure, major adverse cardiovascular events and all-cause death compared to DPP-4i in T2D patients: CVD-REAL Nordic

Event: Heart Failure 2017 - 4th World Congress on Acute Heart Failure

Topic: Population studies / Epidemiology

Session: Clinical Forum - Sat. 29 April 08:30 - Tues. 02 May at 12:30


Periodontal disease - A potential risk factor for myocardial infarction in younger women

Event: ESC Congress 2016

Topic: Epidemiology, lipids

Session: Cardiovascular risk in populations


ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb